ImmuCell
Highly Engaged Employees
Highly Engaged EmployeesBlood & Organ Banks · Maine, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
56 Evergreen Dr, Portland, Maine, 04103,...Phone Number
(207) 878-2770Website
www.immucell.comRevenue
$29.9 MillionStock Symbol
ICCCIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
4
4
3
7
3
2
About ImmuCell
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without a milk discard requirement that provides an alternative to traditional antibiotics.Explore more
ImmuCell Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ImmuCell your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if ImmuCell is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at ImmuCell
Product Launch: Get notified when ImmuCell launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if ImmuCell has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on ImmuCell recently announced quarterly report
Funding: Get notified immidiatlly once ImmuCell has new funding data
Click to see if ImmuCell had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
ImmuCell, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined ImmuCell as Masked Content
Find 3 more new buyers
Compare Similar Companies to ImmuCell
Compare insights from companies similar to ImmuCell, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ImmuCell is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
ImmuCell is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about ImmuCell.
ImmuCell financials insights
Gather financial insights about ImmuCell, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Stock Offering
$5.9M
Share Placement
$3.5M
2017
Multiple Rounds
$10.3M
2019
Stock Offering
$8.3M
2020
Debt
$350K
2021
Share Placement
$4.3M
ImmuCell Tech Stack
A closer look at the technologies used by ImmuCell
Most Recent Scoops
Person-Based
CRM, Account Management, Customer Retention & Development, Customer Success
Earnings
ImmuCell has reported a gross margin of 45% of product sales for Q1 2026.
Earnings, Finance, Manufacturing Operations
Person-Based
Earnings
ImmuCell has reported operating expenses of $2.7 million for Q1 2026, compared to $2.2 million during Q1 2025, driven by increases in general and administrative costs related to leadership investments and higher sales expenses, partially offset by lower product development expenses due to the shift of former Re-Tain-related costs to cost of goods sold.
Earnings, Spending/Investment, Product Development, Sales, Finance
Earnings
Accounting, Logistics / Supply Chain, Financial Reporting, Inventory Management, Finance
ImmuCell News & Media
ImmuCell Q2 Earnings Call Highlights
ImmuCell (NASDAQ:ICCC) reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027. Product sales rose 11.5% year oveImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended June 30, 2026.ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
Conference Call Scheduled for Friday, August 14, 2026 at 9:00 AM ET Conference Call Scheduled for Friday, August 14, 2026 at 9:00 AM ETImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results
PORTLAND, Maine, July 09, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the second quarter of 2026.
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ImmuCell
Sign Up For FreeTo access detailed company insights
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatmen... Read More
